Lemwerder, Germany

Hans-Gottfried Genieser

This inventor holds 6 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Mireca Medicines Gmbh, Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh, Biolog Life Science Institute Gmbh & Co. Kg. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans-Gottfried Genieser. Retrieved from https://idiyas.com/inventor/hans-gottfried-genieser

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 83.3

 

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 15(Granted Patents)


Company Filing History:


Years Active: 2016-2026

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations of Hans-Gottfried Genieser

Introduction

Hans-Gottfried Genieser is a notable inventor based in Lemwerder, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of cyclic nucleotide analogues. With a total of five patents to his name, Genieser has focused on innovations that modulate the cGMP-signaling system.

Latest Patents

One of his latest patents is titled "Polymer linked multimers of guanosine-3', 5′-cyclic monophosphates." This invention is directed towards new polymer linked multimeric guanosine-3',5′-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system. These analogues preferably exhibit activating properties and are designed to activate cGMP dependent protein kinase (PKG). The invention also includes related monomeric precursors that may show modulating activity and serve as reagents for signal transduction research. Another significant patent is "Equatorially modified polymer linked multimers of guanosine-3', 5′-cyclic monophosphates." This invention focuses on new equatorially modified polymer linked multimers that inhibit the cGMP-signaling system. Similar to the previous patent, it also relates to monomeric compounds that may serve as precursors and have inhibitory activity.

Career Highlights

Throughout his career, Genieser has worked with various companies, including Mireca Medicines GmbH and Biolog Life Science Institute GmbH & Co. KG. His work has significantly impacted the field of signal transduction and has contributed to advancements in therapeutic applications.

Collaborations

Genieser has collaborated with notable colleagues such as Andreas Rentsch and Valeria Marigo. These collaborations have further enhanced his research and development efforts in the field of cyclic nucleotide analogues.

Conclusion

Hans-Gottfried Genieser is a distinguished inventor whose work in cyclic nucleotide analogues has led to important advancements in biochemistry. His patents reflect a commitment to innovation and research that continues to influence the scientific community.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…